CalciMedica, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 0.00 shares.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 15.19K shares, a 18.17% increase from fiscal 2024.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 12.85K shares.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 353.51K shares, a 565.31% increase from fiscal 2020.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 53.13K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-12 | |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 15.19K shares 10-K · filed 2026-03-03 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 12.85K shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 11.76K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | |
| 2021-12-31 | 353.51K shares 10-K · filed 2022-03-11 | |
| 2020-12-31 | 53.13K shares 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |